Research Paper Volume 13, Issue 4 pp 5946—5966

Multi-omics analysis identifies potential mechanisms of AURKB in mediating poor outcome of lung adenocarcinoma

The expression of AURKB in LUAD patients and its association with clinical characteristics. (A) AURKB expression difference between lung adenocarcinoma samples and normal samples; (B–E) AURKB expression in different subgroups characterized by TNM staging system (B) T for tumor size; (C) N for lymph node invasion; (D) M for distant metastasis; (E) stage); (F) AURKB expression in smokers and non-smokers. (G) Meta-analysis of AURKB expression in tumor and normal tissues based on different datasets by Lung Cancer Explorer (LCE).

Figure 1. The expression of AURKB in LUAD patients and its association with clinical characteristics. (A) AURKB expression difference between lung adenocarcinoma samples and normal samples; (BE) AURKB expression in different subgroups characterized by TNM staging system (B) T for tumor size; (C) N for lymph node invasion; (D) M for distant metastasis; (E) stage); (F) AURKB expression in smokers and non-smokers. (G) Meta-analysis of AURKB expression in tumor and normal tissues based on different datasets by Lung Cancer Explorer (LCE).